• NASDAQ

908デバイシーズ

MASS医療関連
6.19
  • 15分ディレイ株価

908デバイシーズの掲示板の投稿コメント詳細

908 Devices reported Q3 revenue of $15.8 million, up 26% year over year. This narrowly topped the consensus estimate of $15.7 million. The company posted a net loss of $6.3 million, or $0.20 per share, it wasn't as bad as the average analysts' estimate of a net loss of $0.22 per share.
With better-than-expected top and bottom lines in Q3, why is the healthcare stock falling so much today? You can blame it on 908 Devices' full-year guidance. The company now expects 2022 revenue will be between $46 million and $49 million. Its previous forecast was for full-year revenue in the range of $52 million to $55 million.
908 Devices CEO and co-founder Kevin Knopp explained why the company lowered its revenue outlook in the Q3 results press release. Knopp said that the company saw customers slowing and stretching out their purchase cycles in the recent quarter and he attributed this mainly to macroeconomic headwinds.

これはおもしろい。景気悪くなって、MASSの注文が減っているとの事、、、recessionだね。ここの商品は使用頻度減らそうと思えば減らせそう。

返信

投資の参考になりましたか?

【PR】堅調な伸びを続ける「米国株」について学ぼう!高配当などおすすめ銘柄や選び方は? - マネックス証券 - Yahoo!ファイナンス
米国株の投資信託を探す

最近見た銘柄

JASRAC許諾番号
9008249113Y38200